Nature Medicine 'Under Consideration': What Each Status Means and Realistic Timelines

They're short. Usually two to three sentences. Something along the lines of: "We've considered your manuscript carefully and concluded it isn't suitable for Nature Medicine. We suggest you consider [other journal]." Don't expect detailed feedback. With the volume they handle, they can't provide it.

If the rejection letter suggests a specific Nature Portfolio journal (Nature Communications, Nature Immunology, Nature Cancer, etc.), pay attention. The editors have a good sense of where work fits across the portfolio, and that suggestion is genuine.

The editors are professional (not practicing academics), and they're looking for a specific combination:

• Direct clinical relevance. The paper must speak to something that matters for patient care, diagnostics, or treatment.
• Mechanistic depth. This separates Nature Medicine from purely clinical journals like NEJM or The Lancet. You can't just show a treatment works; you need to show why.
• Broad readership appeal. A finding that matters deeply to pediatric endocrinologists but wouldn't interest anyone outside that subspecialty probably won't clear the desk.
• Study design that matches the claims. Underpowered studies, retrospective analyses presented as prospective, and single-center findings generalized to broad populations are desk rejection triggers.

Here's a specific failure pattern: a paper with excellent basic science data and a final paragraph saying "these findings may have clinical implications." That last paragraph doesn't make a basic science paper clinical. Nature Medicine editors can spot that framing from the abstract alone, and they'll reject it before reading the Methods section.

Days 1 to 3: Your files are being checked for completeness. Don't refresh the portal.

Days 3 to 7: A primary editor picks up your manuscript and reads it against the criteria above. This is the most consequential 48 to 72 hours of your submission.

Days 7 to 10: If you're going to be desk rejected, it almost always happens here. If your status still shows "Under Consideration" on day 10, that's encouraging.

Days 10 to 14: The editor is looking for 2 to 3 reviewers who can evaluate both clinical significance and scientific rigor. It's not unusual for the first round of reviewer invitations to be declined.

Days 14 to 45: Active peer review. Reviewers typically get 2 to 3 weeks. In practice, at least one is usually late.

Days 45 to 60: Getting long but not unusual. Something might be stuck (a reviewer dropped out, a replacement was invited), but it's still within normal range.

Beyond 60 days: A polite inquiry is reasonable and expected.

Nature Medicine isn't just a clinical journal, and it isn't just a basic science journal. It demands both.

The clinical researcher's mistake: A well-designed trial with clear endpoints but no mechanistic insight into why the intervention works. This paper belongs at NEJM, The Lancet, or JAMA.

The basic scientist's mistake: Elegant mechanistic work in disease-relevant models with a concluding paragraph arguing for clinical translation. Unless you have actual patient data or a clear bridge to human disease, this belongs at Nature Cell Biology or Nature Immunology.

Nature Medicine lives in the overlap. The papers that succeed typically include both patient-derived data and mechanistic experiments.

Nature Medicine covers a wide spread of translational and clinical study types, from biomarker work to public-health studies to hybrid preclinical-clinical papers. That breadth can create longer internal comparison windows than authors expect. Silence is often the journal deciding whether the paper is better understood as translational medicine, a basic-science flagship submission, or a clinical-journal story, not simply admin delay.

Reject after review. The most common outcome even for papers that made it past the desk. The reviewers found problems that can't be fixed in revision, or they concluded the clinical advance wasn't substantial enough. A post-review rejection from Nature Medicine is still a strong signal about your work, it means professional editors thought the paper was worth sending out, which isn't nothing.

Major revision. Good news, despite the intimidating label. The editors believe the paper could be publishable if you address the reviewers' concerns. But "address" at this journal usually means new experiments, additional patient cohorts, extended follow-up data, or independent validation. It doesn't mean rewriting a few paragraphs. You'll typically get 3 to 6 months. Use all of it if you need to.

Minor revision. Rare on first round. If you get one, you're almost certainly going to be accepted. Address every point systematically.

Accept. Almost never happens without at least one round of revision.

If you receive a revision request, you're in a small minority of submissions. Nature Medicine revisions aren't cosmetic.

The revision letter will be detailed. Expect 3 to 5 pages of reviewer comments, often with specific requests for new experiments, additional cohorts, or reanalysis of existing data. The editor will also flag which reviewer concerns are mandatory and which are suggestions.

Your point-by-point response matters as much as the revised manuscript. Address every single comment, even the ones you disagree with. When you disagree, explain why with data, not opinions. Reviewers remember when their concerns are dismissed without evidence.

The revised paper usually goes back to the same reviewers. Don't assume a new reviewer will see things differently. Occasionally the editor adds a fourth reviewer if the revision introduced new methods or data the original reviewers aren't qualified to evaluate.

Acceptance after revision isn't guaranteed. Roughly 60 to 70% of papers invited to revise eventually get accepted. The most common failure: the revision didn't fully address the reviewers' core concern, or new data weakened rather than strengthened the original claims.

Write: "Dear [Editor name or Editorial Team], I'm writing to inquire about the status of manuscript NMED-XXXXXXX, submitted on [date]. I would appreciate any update on the expected timeline for a decision. Thank you for your time."

Don't attach new data. Don't summarize the paper. Just ask for a timeline.

If the clinical data is strong but mechanism is thin:

• NEJM or The Lancet for practice-changing trials
• Disease-specific top journals (Journal of Clinical Oncology, Circulation, Gastroenterology)

If the mechanism is strong but clinical data is limited:

• Nature if the finding is broad enough
• Nature sub-journals for mechanistic work in specific domains

If the paper is solid but not broad enough:

• Nature Communications is the natural landing spot for many Nature Medicine desk rejections
• Science Translational Medicine sits in a similar translational space

Don't treat a desk rejection as a comment on your science. The journal receives thousands of submissions per year and publishes a tiny fraction. Most rejected papers find good homes elsewhere.

In our pre-submission review work with manuscripts targeting Nature Medicine, three failure patterns generate the most consistent desk-rejection outcomes.

Mechanistic data without a human disease anchor. We observe this in papers that present excellent cell-line or animal-model biology with a conclusion paragraph arguing for clinical implications. Nature Medicine editors read this pattern in the abstract: compelling mechanism, mouse or cell data throughout, final sentence about "implications for therapeutic targeting of X." The journal requires that human relevance be present in the data, not only in the discussion. A PDX model or patient-derived organoid does not substitute for a primary patient cohort in most cases. Manuscripts that cannot answer the question "where are the patients?" in the figures typically do not clear the desk screen.

A clinical study without mechanistic depth. We observe this when authors submit well-designed trials or large cohort studies that demonstrate a clear clinical signal but do not explain the biological mechanism underlying the effect. A phase II trial showing improved progression-free survival, or a biomarker study identifying a predictive signature, belongs at NEJM, The Lancet, or JAMA if the paper cannot also explain why the biology works the way it does. SciRev community data for Nature Medicine consistently identifies the absence of mechanistic follow-up as the most common reason for post-desk rejection at this journal, particularly for papers submitted from strong clinical groups that have the outcome data but not the mechanistic layer.

A translational claim that requires two inferential steps. We observe this when the experimental bridge between the laboratory finding and the clinical application involves a chain of assumptions rather than direct evidence. Nature Medicine editors are reading for a direct, defensible path from mechanism to patient. Papers that require readers to accept that a finding in one model system generalizes to a different disease context, and then to accept that the disease context generalizes to a treatment approach, face consistent reviewer pushback on the translational chain even when each individual step is scientifically sound.